Sanofi rimonabant is Acomplia
Executive Summary
Brand name for rimonabant will be Acomplia, Sanofi-Synthelabo says during investor presentation Feb. 16. Sanofipresented positive Phase III results of the selective cannabinoid (CB1) receptor antagonist in smoking cessation and obesity clinical trials. The company expects to complete trials by the end of the year and file an NDA by the second quarter of 2005...
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.